New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

Epilepsy & Seizures

Updated 06.16.2024
Released 06.21.2023
Expires For CME 06.16.2027

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

Authors: Nicolas Gaspard PhD, Claudine Sculier MD

See Contributor Disclosures

Editor: Solomon L Moshé MD

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

In This Article

Quick Link

Introduction

Overview

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) are rare and devastating conditions that have been described 20 years ago (Van Lierde gopaul 2003). Consensus definitions now propose a unifying and standardized framework for NORSE and FIRES (37). According to these definitions, NORSE is a clinical presentation, not a specific diagnosis, with the occurrence of de novo refractory status epilepticus in a patient without active epilepsy or other preexisting relevant neurologic disorder and without a clear acute or active structural, toxic, or metabolic cause. Usually, this means that history, examination, and initial ancillary investigations performed within the first 48 hours do not provide sufficient clues to establish a causal diagnosis. FIRES is a subgroup of NORSE preceded by a febrile illness between 2 weeks and 24 hours prior to the onset of refractory status epilepticus, with or without fever at the onset of status epilepticus (37). These apply to all ages. Emerging evidence suggests that immune dysregulation would trigger the status epilepticus onset and induce the long-term sequelae. Early immunotherapy is now recommended, even if the exact mechanism is still largely unknown.

Historical note and terminology

Historically, the acronym NORSE has been used variably and without a clear definition to describe cases of refractory status epilepticus of unknown etiology (95; 10; 48). In children, the related condition of FIRES has been studied under many different names (73; 05; 53; 63; 75; 52; 87). This nosological complexity made this entity difficult to study. As NORSE and FIRES share many similarities, they are now considered to belong to the same clinical entity, and both terms can be used for children and adults, although FIRES was initially mainly described in children (65; 52).

Consensus definitions now allow clinicians to work on a common framework (37). NORSE includes cases of unknown etiology (cryptogenic NORSE or c-NORSE) if no cause is found despite extensive investigations as well as cases with a known etiology when a diagnosis is ultimately reached through these investigations.

An international survey revealed important gaps (94). Two-thirds of responding institutions did not have a protocol for NORSE cases, and a quarter do not even perform an autoimmune work-up (94). This survey provided the opportunity the write consensus recommendations for management and treatment of NORSE, which are still mainly experience-based on expert opinions through a Delphi study and literature review. Those standardized protocols are not strict guidelines, but they should improve the management of those patients, the diagnostic yield, as well as the communication between clinicians and with patients and their relatives. They also make the collection of more homogeneous and complete data easier to create larger multicentric cohorts of patients and help further research.

An etiology is identified in approximatively 30% of NORSE cases (21; 60; 56; 33). The majority of adult cases with a known etiology are due to sporadic or paraneoplastic autoimmune encephalitis (21). In many case series of children with FIRES, the cause most often remains unknown, but the lack of etiological diagnosis is likely an inclusion criterion for most studies, introducing a selection bias (63; 52; 08; 67; 87; 79). Recent findings have increased our understanding of cryptogenic cases, which support the hypothesis of a postinfectious autoinflammatory mechanism (84; 56; 31).

Clinical manifestations

Presentation and course

NORSE and FIRES follow a biphasic course, with a prodromal phase preceding the onset of status epilepticus and encephalopathy by up to 2 weeks. Status epilepticus often has a subacute onset over a few hours to days. The prodromal phase, which is characterized by nonspecific mild illness with gastrointestinal, upper respiratory, or flu-like symptoms, often precedes the onset of seizures (21; 79). Headaches and hallucinations are also often reported (44). In children, a preceding febrile episode, which defines FIRES, is almost always reported (90%) (79; 96). In adults, fever is reported in only 30% to 50% of cases (21; 60), although it seems to be more frequent in cryptogenic cases (60% to 90%) (21; 43; 11). This difference could be explained by the greater propensity of fever to appear or be noticed in children than in adults (44).

Seizures typically appear between 24 hours to 2 weeks after the prodromal phase, often with a short free interval. Cognitive and behavioral symptoms, including hallucinations and memory difficulties, can occur before or at the same time as seizures. Seizures are initially brief and infrequent, increasing within a few hours to days in frequency (up to hundreds per day) and severity, together with progressive impairment of consciousness. They quickly evolve into status epilepticus that persists or recurs despite administration of anesthetics in continuous infusion, corresponding to (super) refractory status epilepticus requiring intensive care. The most frequent seizure type is focal seizure with or without impairment of awareness and with secondary bilateralization and multifocal onset (52; 40; 21). A temporal-perisylvian semiology is often seen (66).

Bilateral independent temporal electrographic seizures in febrile infection-related epilepsy syndrome of unknown etiology

Four consecutive 20-second EEG pages showing a right temporal onset electrographic seizure in a 33-year-old patient with febrile infection-related epilepsy syndrome of unknown etiology. (Contributed by Dr. Nicolas Gaspard.)
Bilateral independent temporal electrographic seizures in febrile infection-related epilepsy syndrome of unknown etiology (2)

Four consecutive 20-second EEG pages showing a left temporal onset electrographic seizure. Settings: sensitivity 70 µV/cm; low-pass filter 70 Hz; high-pass filter 0.53 Hz. (Contributed by Dr. Nicolas Gaspard.)

Prognosis and complications

The episode of status epilepticus can last several days or weeks. The majority of FIRES and NORSE cases evolve to super-refractory status epilepticus, which is defined as status epilepticus persisting for at least 24 hours, or recurring while on appropriate anesthetic treatment, or reoccurring after withdrawal of anesthesia. In adults, the median duration of status epilepticus is 17 days and of ICU stay is 15 to 30 days (21; 60; 11). The mortality rate in adult NORSE is 16% to 27% (10; 19; 21; 48; 33). Long-term outcome is often poor, with half to two-thirds of the survivors developing cognitive impairment, behavioral disorder, and functional disability (05; 53; 65; 75; 40; 08; 21; 67; 87; 79; 11). Subsequent drug-resistant epilepsy develops without a latent period in greater than 60% survivors (85; 11; 33). A diffuse brain atrophy appears in one to two thirds of cases in both adults and children (53; 40; 08; 43). Diffuse brain atrophy appears in up to two third of cases both adults and children (53; 40; 08; 43; 33).

In children, the range of status epilepticus duration varies across the literature. A retrospective case series of 92 children with NORSE, including 90% with FIRES, showed a median ICU stay of 5 days, with a status epilepticus duration of 8 days (96). The mortality was 23%, similar to adults, with 40% of survivors having poor functional outcome. Previous studies on pediatric FIRES tended to report longer status epilepticus duration (52) but lower mortality rates (12%) and worse outcome on survivors, with refractory residual epilepsy in many of them and 50% to 60% with cognitive disability (half of them severe, including vegetative state) (52; 79). Executive dysfunction is most prominent (63; 52).

Super-refractory status epilepticus (96), diffuse cortical edema or multifocal abnormalities observed on MRI (96), nonconvulsive status epilepticus (96), young age (52), and duration of barbiturate coma (52) were the factors associated with worse outcome. It is unclear if this association indicates an independent effect of anesthesia or if it reflects the intrinsic severity of the underlying disease that required more intensive treatment.

Biological basis

Etiology and pathogenesis

NORSE and FIRES cover a heterogeneous group of disorders. In approximately 30% of cases, a definite etiology is ultimately found. Despite an extensive workup, greater than 75% (21; 60) and children (52; 96) with NORSE and FIRES remain of unknown etiology (also known as cryptogenic NORSE or c-NORSE). These cases might share a common pathogenesis.

Overall, clinical features are similar in c-NORSE and autoimmune cases. However, the status epilepticus tends to be more refractory with response to first-line immunotherapy, far more disappointing than expected in autoimmune encephalitis, mainly in children. They often have a worse outcome, with residual refractory epilepsy in more than 90% of survivors and cognitive sequelae in more than 80% of FIRES (63; 75; 52; 40; 79). Only 4% of c-NORSE patients return to baseline, and 40% achieve favorable functional outcome (11).

Immunology. Even if the exact pathogenesis is still not fully understood, several studies suggest that FIRES and NORSE of unknown etiology might be due to post-infectious genetically determined autoinflammatory mechanisms (89), involving cytokines and chemokines of the Th1-related immunity and inflammation pathways (76; 46; 45; 09; 51; 41). A study showed specific immune signatures of NORSE and FIRES of unknown etiology, compared to patients with refractory status epilepticus and NORSE with a known etiology, characterized by increased serum levels of C-X-C motif ligand (CXCL)8, C-C motif ligand (CCL)2, macrophage inflammatory protein (MIP)1a, and interleukin (IL)10 and IL4, and increased CSF levels of IL1beta (31). The level of several of these cytokines correlated with daily ictal burden, severity, and worse outcome (31). Cytokine levels are also more elevated in children with FIRES than in adults (44). These cytokines are possibly produced by hyperinflammatory macrophages that exhibit abnormal response to exogenous triggers, such as viral or bacterial antigens (39). Of note, the abnormal cytokine profile found in NORSE and FIRES of unknown etiology differs from the one observed in antibody-mediated autoimmune encephalitis, which results from a response of the adaptive immune system with elevations in TNF-alpha, IL-2, IL-12, IL-4, and IL-10 and may explain the greater response to first-line immunotherapies in these conditions (45). Several of the cytokines elevated in cryptogenic cases are known to increase neuronal excitability in vivo, either directly or indirectly, through a variety of mechanisms. In turn, seizures themselves can further activate the immune system through the increase of cytokine levels, by activated glia and blood-brain barrier leakage, thus, creating a self-perpetuating cycle of inflammation and hyperexcitability. Studies are ongoing to further investigate these mechanisms at the single-cell level (33).

Genetics. The autoinflammatory mechanism underlying the pathogenesis of NORSE and FIRES of unknown etiology is driven in part by genetic predisposition. Genetic studies have revealed the presence of polymorphisms in the IL1RN gene, which codes for a soluble antagonist of the IL-1beta receptor (sILRA) that modulates the IL-1beta pathway in patients with cryptogenic FIRES. The resulting sIL1RA protein appears to be functionally deficient, leading to an increase of IL-1beta production (50; 09). Another study demonstrated that children with cryptogenic FIRES have defective toll-like receptor (TLR) signaling despite normal TLR expression on peripheral monocytes, as well as decreased naive T and T regulatory cells and weakened phagocytosis (41). This could not only increase the hosts’ susceptibility to viral infections but also decrease their ability to eradicate pathogens. In turn, prolonged exposure to viruses and accumulated cell and pathogens debris, in conjunction with decreased T regulatory cells, could promote autoimmunity and autoinflammation. Thus, these studies imply a genetic predisposition to cryptogenic NORSE and FIRES (74; 09) and provide the first hint towards the mechanisms that lead to increased levels of anti-inflammatory cytokines in patients with NORSE or FIRES (09; 51). Altogether, cryptogenic NORSE and FIRES would then result from an aberrant post-infectious neuroinflammatory response.

In line with this hypothesis, several case reports and series have described spectacular clinical and electrographic responses to therapies targeting the innate inflammatory pathway like anakinra, a recombinant IL-1 receptor antagonist, or tocilizumab, an IL-6 receptor antagonist (46; 45; 14; 72; 93; 55; 83; 98; 01). Use and effect of those treatments are detailed in the therapy section below.

Differential diagnosis

Associated or underlying disorders

The possible causes of NORSE and FIRES are many (56). They can be classified into four categories: (1) inflammatory and autoimmune encephalitis, (2) uncommon infectious encephalitis, (3) genetic disorders, and (4) toxic disorders (20).

The etiologies vary with age. For instance, a paraneoplastic etiology is more frequent in adults (18%) than in children, whereas uncommon infection is more frequently reported in children than adults (20% vs. 10%) (21; 26; 42; 96; 56). Metabolic and genetic etiologies, including mitochondrial diseases, are also more frequent in children, but they can rarely present with NORSE in adulthood.

In young adults, the most frequently identified cause is autoimmune encephalitis (19% to 37% of all NORSE cases) (21; 60), including sporadic and paraneoplastic cases. Antibodies directed against neuronal cell surface antigens are the most involved. The most frequently identified antibodies target the N-methyl-D-aspartate (NMDA) receptor (12% to 15%). Antibodies against leucine-rich glioma inactivated 1 (LGI1) (21; 56), gamma-aminobutyric acid (GABA)bR, and GABAaR are also found. NORSE associated with onconeuronal antibodies also exist (21). Antibodies are exceptionally found in pediatric cohorts (3%) (79; 96), with anti-NMDA, contactin-associated protein-like 2 (Caspr-2) (96), or GABAaR (56). One study found anti-glutamate receptor (GluR) epsilon 2 antibodies in the CSF of a few FIRES cases, but their role and significance remain unknown (75).

Some clinical features can suggest a specific underlying etiology and are important to recognize. For instance, paraneoplastic limbic encephalitis is characterized by cognitive impairment, behavioral changes, sleep disturbances, and seizures with eventual progression to status epilepticus (03; 20). Anti-NMDA receptor encephalitis is the first cause of overall autoimmune encephalitis (13) and often starts with febrile illness. Patients then develop psychiatric symptoms manifesting in children as behavioral disturbances and tantrums. Children are more likely to present movement disorders, seizures, and status epilepticus than adults (18; 03; 70). Language regression, hyperactivity, and irritability are often seen, followed by progression to decreased responsiveness and severe catatonic stage, with typical orolingual dyskinesia and autonomic failure (70). The EEG shows a specific pattern of “extreme delta brushes” in 50% of cases (77; 30). Encephalitis with antibodies targeting the voltage-gated potassium channel (VGKC) complex (LGI1 or, more rarely, CASPR2) are associated with limbic encephalitis and a syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Pathognomonic faciobrachial dystonic seizures can occur in anti-LGI1 encephalitis.

Although genetic investigations are usually disappointing (02; 36), a few mutations have occasionally been identified in sporadic NORSE and FIRES cases (42; 96; 91; 94; 23), including point mutations in the KCNT1 (potassium sodium-activated channel subfamily T member 1), CACNA1A (calcium voltage-gated channel subunit alpha1A), POLG1 (DNA polymerase gamma subunit 1), PCDH19 (protocadherin 19), cathepsin D, CEP290 (centrosomal protein of 290 kDa), POU1F1 (POU class 1 homeobox 1), FADD (FAS-associated protein with death domain), and DNM1L (dynamin 1 Like) genes and a chromosomal 9p24.3 chromosomal duplication.

Diagnostic workup

Both brain MRI and CSF analyses are the first procedures required when a diagnosis of NORSE or FIRES is suspected in order to exclude other causes of acute symptomatic status epilepticus, like stroke or infectious encephalitis. The second step aims to identify eventual causes of NORSE, mainly using antibody panels and metabolic and genetic analyses.

CSF. Half to two thirds of cases present with mild CSF pleocytosis (usually less than 10 cells/µl) and slightly increased CSF protein level (52; 21). By definition, first-line microbiological studies should be negative.

MRI. In the acute phase, about 30% to 50% of pediatric (79; 96) or adult (21; 60) NORSE cases have an abnormal initial MRI. The most frequent finding is with T2/FLAIR hypersignal located in limbic or neocortical areas, often bilaterally and symmetric (43). In children, diffuse cerebral edema is often reported (12; 96). Basal ganglia (63), claustrum (62; 61), and peri-insular (08) involvement have also been reported. Two studies have highlighted the presence of peculiar, and possibly specific, transient bilateral claustral T2/FLAIR changes in adult and children with NORSE or FIRES of unknown etiology (62; 61). It is unclear if these findings are specific to NORSE or if they are the consequence of prolonged ictal activity. A normal MRI is possibly associated with better outcome in children (79; 96).

Imaging abnormalities in new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) of unknown etiology

(A) Bilateral FLAIR hyperintensities in the claustrum on MRI 12 days into the acute phase of FIRES of unknown etiology in a 33-year-old patient. (B) Disappearance of these hyperintensities on a 6-month follow-up MRI. (C) Unilat...

EEG. The EEG reveals sporadic or periodic epileptiform discharges, which can be lateralized, bilateral independent, or multifocal, often involving the temporal and frontal regions. Generalized discharges have also been reported, mainly in children (50%) (21; 79). A retrospective study identified three EEG findings in FIRES: (1) beta-delta complexes (20%) (60), (2) seizure onset with prolonged focal fast activity, followed by the gradual appearance of well-formed rhythmic spike or spike-and-wave complexes, and (3) shifting ictal activity (17). Those findings should be confirmed by further studies. Continuous EEG monitoring is indicated as most seizures in refractory and super-refractory status epilepticus are either purely electrographic or clinically too subtle to allow clinical monitoring.

C-NORSE score. No validated test is available to identify NORSE and FIRES cases of unknown etiology (in the first hours of status epilepticus onset). Therefore, the diagnosis is established only after a few days, which is the time required to obtain the results of autoimmune screening. As data suggest quickly treating patients more aggressively, an earlier diagnosis is required (94). A cryptogenic NORSE score has been proposed for this purpose (97). This score includes the following features: presence of prodromal high fever of unknown origin before the onset of status epilepticus, absence of prodromal behavioral or memory alterations before onset of status epilepticus, absence of sustained orofacial-limb dyskinesias despite a profoundly decreased level of consciousness, and symmetric brain magnetic resonance imaging abnormalities. Each feature is worth 1 point, and a high score suggests crypotgenic NORSE. The sensitivity and specificity of a high score for predicting C-NORSE are 94% and 100%, respectively, potentially easing the decision to initiate immunotherapy targeting the innate immune system as early as 48 hours from the onset of status epilepticus.

Autoimmune, metabolic, infectious, and genetic testing. Because of the rarity of the syndrome, work-up strategies markedly vary between institutions and clinicians (56). Whereas infectious and autoimmune testing are often performed, genetic testing is performed in only a minority of cases.

Delphi methodology-based consensus recommendations for standardized work-up are now available and should improve diagnostic yield (94). According to these guidelines, an initial standardized diagnostic workup is recommended for all NORSE and FIRES cases, regardless of age and the presence of a prodromal febrile episode (94). This initial work-up should mostly aim to identify autoimmune and infectious encephalitis, and complete autoimmune workup is essential in any NORSE case given that autoimmune encephalitis is the most frequent identified cause of NORSE in adults.

Based on the results of this initial work-up, further investigations need to be tailored according to the patient's characteristics (80). For instance, young children should more promptly undergo extensive metabolic and genetic investigations as the yield of these investigations is higher in this age group. Immunosuppression and known exposure to potential pathogen vectors should heighten the suspicion of uncommon infectious causes (94). A malignancy screen, including whole body PET, should be considered in older adults. However, early testing for autoimmune antibodies should nearly always be done in all NORSE cases as results will impact the treatment choice.

Neuropathology. Very little data are available, and findings are variable. The most frequent findings include neuronal loss, reactive gliosis, microglial activation, meningeal inflammation, and perivascular T-cell infiltration (31).

Management

There is no randomized controlled trial for the treatment of NORSE patients, and most institutions do not have standardized protocols to manage them. Recommendations have been published, relying on expert opinion through a Delphi method, in an effort to share experiences and create a unified standardized approach (94). Second-line immune therapies seem to be increasingly used (33).

The initial treatment of NORSE and FIRES in the first 24 to 48 hours does not differ from the treatment of status epilepticus in general. Early status epilepticus requires prompt treatment, usually with a parenteral benzodiazepine and, if unsuccessful, with an IV load of a nonsedating antiseizure medication. When refractoriness is established, patients should ideally be admitted in a tertiary center with continuous EEG available and multidisciplinary expertise. The course of the treatment is then guided by continuous EEG to identify electrographic seizures, as it is recommended for all patients with refractory status epilepticus (94). Treatment of NORSE with antiseizure medications is often disappointing. At least 75% of patients require anesthetics in continuous infusion and often prolonged burst-suppression coma to stop the seizures. Status often resumes once the anesthetics are weaned off (52; 89). Of note, some FIRES experts recommend avoiding anesthetics in continuous infusion as it has been associated with poor outcome in several studies; however, those data could reflect allocation bias, as the more severe cases likely received more intensive sedation (49).

Once the situation is recognized as NORSE, usually within 48 to 72 hours from the onset of status epilepticus, early immunotherapy is recommended. In cryptogenic and proven or suspected autoimmune NORSE, corticosteroids are the most common first-line treatment, often combined with IVIG. But IVIG alone can be used if an infectious etiology is strongly suspected and has not yet been excluded (94). If the patient does not improve, experts suggest initiating the ketogenic diet, mostly in children, or second-line immunotherapies within 1 week of the onset of status epilepticus once infectious etiologies have formally been ruled out. Response to first-line immune therapies in antibody-mediated cases is often better than in cryptogenic cases, and rituximab can be administered as a second-line therapy.

In cryptogenic NORSE and FIRES, response to first-line therapies and rituximab is often disappointing, and other second-line immunotherapies should be initiated (75; 52; 88; 84).

Given the suspected underlying role of the innate immune system, immunotherapy blocking proinflammatory innate cytokines, such as anakinra, tocilizumab, intrathecal dexamethasone, and the ketogenic diet have been tried, with promising results (45; 14; 38; 33).

Anakinra. Overall, approximately 70 patients, mostly children with cryptogenic FIRES, have been reported in the literature. A retrospective cohort of 25 children showed that earlier initiation of anakinra was associated with shorter duration of hospital stay, and 11 out of 15 children had a more than 50% decrease in seizure burden after 1 week (55). This treatment was also associated with normalization of IL-8 and IL-6 levels, with an improvement of epilepsy in several cases (46), suggesting that inflammation biomarkers could be used to assess treatment efficacy (54). Despite the occurrence of severe adverse reactions in two thirds of patients, mainly cytopenia and infections, anakinra was rarely discontinued (55). A risk of DRESS syndrome also exists (71).

Tocilizumab. Overall, approximately 35 patients, mostly adults with cryptogenic FIRES or nonfebrile NORSE, have been reported in the literature. Tocilizumab was also reported to be successful in six of seven adult patients with NORSE, with status epilepticus resolved after one or two doses and an interval of 3 days from the onset of treatment. Better outcome was associated with earlier treatment. Adverse events occurred in five patients: leukopenia in three cases, sepsis, and pneumonia (45). Several case reports also highlighted the efficacy of this treatment, both in children and adults (07; 15; 92), and even in FIRES cases refractory to anakinra (83; 01). The experts recommend starting either anakinra or tocilizumab within the first week of onset of status epilepticus. Measuring serum and CSF IL-6 levels in the first few days could be useful to monitor the response to treatment (24).

Current evidence does not support the use of one over the other molecule. Tocilizumab is a larger molecule than anakinra and can be less effective in penetrating the blood brain barrier (59). Consequently, the peripheral concentration of IL-6 could increase and induce a paradoxical neurologic deterioration (28). The duration of treatment is not yet well defined, and further studies are required to provide evidence-informed recommendations for both drugs, which are currently not FDA or EMA approved for this indication. If well tolerated, immunomodulation treatments should be continued for 3 months, especially if cytokines were increased in the acute phase (94).

Intrathecal dexamethasone. The use of intrathecal dexamethasone (IT-DEX) has been reported in a total of 11 patients, including nine children. In the initial report of 6 children with FIRES IT DEX was administered at least four times with an interval of 1 to 6 days. This allowed reduction of 50% of seizure burden in three of them with improvement of EEG background (38). The main advantage of IT-DEX compared to anakinra and tocilizumab seems to be the absence of severe adverse event.

Ketogenic diet. The use of the ketogenic diet in NORSE and FIRES was reviewed (64). It was first reported to be successful in seven of eight children with FIRES, with improvement noted after 1 to 4 days of ketonuria (65). This was further confirmed by a case series in which all seven children improved by ketogenic diet, which was sometimes administered by intravenous line (68). The efficacy of the ketogenic diet in super-refractory status epilepticus in adults, including possible NORSE cases, has also been suggested (86). In FIRES, ketogenic diet should be introduced within 2 to 5 days of the onset of status epilepticus (49). There have been several reports on the efficacy and safety of the ketogenic diet in this setting; a total of 72 cases were included in a systematic review of the ketogenic diet in pediatric super-refractory status epilepticus (78). Overall, ketosis was achieved in 96% of cases, within a mean time of 3.4 days, and status epilepticus resolved in 60% of cases, within a mean of 6.3 days after the initiation of ketogenic diet. Adverse events occurred in a third of children and were mostly mild gastrointestinal side effects. Hypoglycemia, metabolic acidosis, weight loss, and nephrolithiasis occurred in less than 5% of cases (81). The ketogenic diet induces an anti-inflammatory process through the inhibition of IL-1beta and, therefore, could act in synergy with anakinra (69).

Other less common treatments have been proposed. In a few cases series on refractory status epilepticus, hypothermia at 33°C was found to be effective in controlling seizures in adults or children (57), but only rare case reports refer to NORSE or FIRES (58). The risk of complication is substantial, manly aspiration pneumonia. Thus far, there are no sufficient data to recommend this therapeutic option. Cannabidiol is a potential alternative therapy in epilepsy (04) and has been shown to improve seizure frequency and duration in six out of seven children with FIRES, but mainly in the chronic phase (25). Electroconvulsive therapy and neurostimulation with vagal nerve or deep brain stimulation have also been anecdotally used (82).

All these therapeutic options need to be validated by large and prospective studies. A suggested algorithm for the use of these therapies is summarized, with their suggested dosing.

NORSE treatment algorithm: commonly used drugs in NORSE with most frequently reported doses (expert opinion)

Legend: c-NORSE, cryptogenic NORSE; IV, intravenous; IVIG, intravenous immunoglobulin; RSE refractory status epilepticus; SE, status epilepticus; SC, subcutaneous.

Adapted from:
Wickstrom R, Taraschenko O, Di...

Outcomes

Even fewer data are available concerning epilepsy in the post-acute phase of NORSE and FIRES. Combinations of multiple antiseizure medications are usually administrated given the residual refractory epilepsy in those patients. No specific medication can be preferentially recommended. Most treatment initiated in the acute phase with an effective response can be continued in the post-acute phase (94), but in most cases, long-term immunotherapies are limited by the risk and occurrence of side effects. The doses can sometimes be adapted. For instance, maintenance steroids should be avoided, but intermittent steroid pulses can be considered (47). Long-term immunomodulation for more than 3 months is not encouraged, but re-challenges are sometimes performed in cases of worsening on withdrawal. One small study suggests a positive effect of treatment targeting IL-6 and IL-8 in the chronic phase of the disease, but this needs to be confirmed by larger trials (01). The mechanism of cognitive alteration in NORSE is likely related to the severity and duration of status epilepticus. Persistent inflammation and structural change may also play a role that could explain those successful responses of immunotherapy in the chronic phase (85).

Data on neurostimulation, presurgical work-up, and resective surgery are lacking (94). Psychological and behavioral counseling and family support are often needed.

As explained in the prognosis section, NORSE and FIRES are associated with a high rate of mortality, and most survivors have moderate to severe cognitive disabilities. Therefore, it is recommended to periodically repeat a neuropsychological evaluation in the follow-up care of those patients. Many will need to undertake an intensive program of cognitive rehabilitation (94). Given the retrospective and observational design of most studies, with limited number of patients and heterogeneous protocols, the efficacy and safety of the different treatments cannot be clearly assessed nor compared. Clinical trials with standardized approach are needed, using uniformed scales and tools to measure seizure burden but also functional outcomes, including in the chronic phase.

Media

References

01: Aledo-Serrano A, Hariramani R, Gonzalez-Martinez A, et al. Anakinra and tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome (FIRES): effectiveness and safety from a case-series. Seizure 2022;100:51-5. PMID 35759951
02: Appenzeller S, Helbig I, Stephani U, et al. Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations. Dev Med Child Neurol 2012;54(12):1144-8. PMID 23066759
03: Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol 2012;27(11):1460-9. PMID 22935553
04: Aydemir S, Kandula P. High dose cannabidiol (CBD) in the treatment of new-onset refractory status epilepticus (NORSE). Seizure 2022;94:126-8. PMID 34896815
05: Baxter P, Clarke A, Cross H, et al. Idiopathic catastrophic epileptic encephalopathy presenting with acute onset intractable status. Seizure 2003;12(6):379-87. PMID 12915084
06: Bolle AE, Gaist T, Kuljis AME, Blaabjerg M, Beier CP. NORSE seasonality may vary geographically in adults. Epilepsia Open 2024;9(3):1088-95. PMID 38635008
07: Cantarin-Extremera V, Jiménez-Legido M, Duat-Rodríguez A, et al. Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: experience in two patients. J Neuroimmunol 2020;340:577142. PMID 31935626
08: Caraballo RH, Reyes G, Francisca Lopez Avaria M, et al. Febrile infection-related epilepsy syndrome: a study of 12 patients. Seizure 2013;22(7):553-59. PMID 23643626
09: Clarkson BDS, LaFrance-Corey RG, Kahoud RJ, Farias-Moeller R, Payne ET, Howe CL. Functional deficiency in endogenous interleukin-1 receptor antagonist in patients with febrile infection-related epilepsy syndrome. Annal Neurol 2019;85(4):526-37. PMID 30779222
10: Costello DJ, Kilbride RD, Cole AJ. Cryptogenic new onset refractory status epilepticus (NORSE) in adults-infectious or not? J Neurol Sci 2009;277(1-2):26-31. PMID 19013586
11: Costello DJ, Matthews E, Aurangzeb S, et al. Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE). Epilepsia 2024;65(6):1581-8. PMID 38498313
12: Culleton S, Talenti G, Kaliakatsos M, Pujar S, D’Arco F. The spectrum of neuroimaging findings in febrile infection-related epilepsy syndrome (FIRES): a literature review. Epilepsia 2019;60(4):585-92. PMID 30854647
13: Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7(12):1091-8. PMID 18851928
14: Dilena R, Mauri E, Aronica E, et al. Therapeutic effect of anakinra in the relapsing chronic phase of febrile infection-related epilepsy syndrome. Epilepsia Open 2019;4(2):344-50. PMID 31168503
15: Donnelly JP, Kasatwar N, Hafeez S, et al. Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab. Epilepsy Behav Rep 2021;15:100431. PMID 33748736
16: Dozières-Puyravel B, Höhn S, Auvin S. Considering safety and patient tolerance in the use of ketogenic diet in the management of refractory and super-refractory status epilepticus: a systematic review. Expert Rev Neurother 2021;21(11):1303-8. PMID 34275391
17: Farias-Moeller R, Bartolini L, Staso K, Schreiber JM, Carpenter JL. Early ictal and interictal patterns in FIRES: the sparks before the blaze. Epilepsia 2017;58(8):1340-8. PMID 28555777
18: Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66(1):11-8. PMID 19670433
19: Gall CRE, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 2013;22(3):217-20. PMID 23333762
20: Gaspard N. Unusual causes of status epilepticus. In: Kaplan DF, editor. Status epilepticus. Current clinical neurology. Springer, Cham, 2018:87-110.
21: Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015;85(18):1604-13. PMID 26296517
22: Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives. Epilepsia 2018;59(4):745-52. PMID 29476535
23: Giovannini G, Giannoccaro MP, Cioclu MC, et al. FADD gene pathogenic variants causing recurrent febrile infection-related epilepsy syndrome: Case report and literature review. Epilepsia 2024;65(7):e119-24. PMID 38752438
24: Girardin ML, Flamand T, Roignot O, et al. Treatment of new onset refractory status epilepticus/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult. Epilepsia 2023;64(6):e87-e92. PMID 36961094
25: Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol 2017;32(1):35-40. PMID 27655472
26: Gofton TE, Gaspard N, Hocker SE, Loddenkemper T, Hirsch LJ. New onset refractory status epilepticus research: what is on the horizon? Neurology 2019;92(17):802-10. PMID 30894443
27: Gopaul MT, Hanin A, Cespedes J, et al. The seasonality of new-onset refractory status epilepticus (NORSE). Epilepsia 2023;64(6):e112-7. PMID 37013696
28: Gust J, Hay KA, Hanafi L, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7(12):1404-19. PMID 29025771
29: Haanpaa A, Laakso SM, Kinnunen A, Kämppi L, Forss N. Early clinical features of new-onset refractory status epilepticus (NORSE) in adults. BMC Neurology 2022;22(1):495. PMID 36539824
30: Haberlandt E, Ensslen M, Gruber-Sedlmayr U, et al. Epileptic phenotypes, electroclinical features and clinical characteristics in 17 children with anti-NMDAR encephalitis. Eur J Paediatr Neurol 2017;21(3):457-64. PMID 28017557
31: Hanin A, Cespedes J, Dorgham K, et al. Cytokines in new-onset refractory status epilepticus predict outcomes. Ann Neurol 2023;94(1):75-90. PMID 36871188
32: Hanin A, Cespedes J, Huttner A, et al. Neuropathology of new-onset refractory status epilepticus (NORSE). J Neurol 2023;270(8):3688-702. PMID 37079033
33: Hanin A, Zhang L, Huttner AJ, et al. Single-cell transcriptomic analyses of brain parenchyma in patients with new-onset refractory status epilepticus (NORSE). Neurol Neuroimmunol Neuroinflamm 2024;11(4):e200259. PMID 38810181
34: Hanin A, Muscal E, Hirsch LJ. Second-line immunotherapy in new onset refractory status epilepticus. Epilepsia 2024;65(5):1203-23. PMID 38430119
35: Hanin A, Jimenez AD, Gopaul M, et al. Trends in management of patients with new-onset refractory status epilepticus (NORSE) from 2016 to 2023: an interim analysis. Epilepsia 2024;65(8):e148-55. PMID 38837761
36: Helbig I, Barcia G, Pendziwiat M, et al. Whole-exome and HLA sequencing in febrile infection-related epilepsy syndrome. Ann Clin Transl Neurol 2020;7(8):1429-35. PMID 32666661
37: Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018;59(4):739-44. PMID 29399791
38: Horino A, Kuki I, Inoue T, et al. Intrathecal dexamethasone therapy for febrile infection-related epilepsy syndrome. Ann Clin Transl Neurol 2021;8(3):645-55. PMID 33547757
39: Howe CL, Johnson RK, Overlee BL, Sagen JA, Mehta N, Farias-Moeller R. Drug-resistant seizures associated with hyperinflammatory monocytes in FIRES. Ann Clin Transl Neurol 2023;10(5):719-31. PMID 36924141
40: Howell KB, Katanyuwong K, Mackay MT, et al. Long-term follow-up of febrile infection-related epilepsy syndrome. Epilepsia 2012;53(1):101-10. PMID 22191582
41: Hsieh MY, Lin JJ, Hsia SH, et al. Diminished toll-like receptor response in febrile infection-related epilepsy syndrome (FIRES). Biomed J 2020;43(3):293-304. PMID 32651134
42: Husari KS, Labiner K, Huang R, Said RR. New-onset refractory status epilepticus in children: etiologies, treatments, and outcomes. Pediatr Crit Care Med 2020;21(1):59-66. PMID 31568262
43: Iizuka T, Kanazawa N, Kaneko J, et al. Cryptogenic NORSE: its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm 2017;4(6):e396. PMID 28959704
44: Jimenez AD, Gopaul M, Asbell H, et al. Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection-related epilepsy syndrome) versus without prior fever: An interim analysis. Epilepsia 2024;65(6):e87-e96. PMID 38625055
45: Jun JS, Lee ST, Kim R, Chu K, Lee SK. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol 2018;84(6):940-5. PMID 30408233
46: Kenney-Jung DL, Vezzani A, Kahoud RJ, et al. Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol 2016;80(6):939-45. PMID 27770579
47: Kessi M, Liu F, Zhan Y, et al. Efficacy of different treatment modalities for acute and chronic phases of the febrile infection-related epilepsy syndrome: a systematic review. Seizure 2020;79:61-8. PMID 32417686
48: Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)--the potential role for immunotherapy. Epilepsy Behav 2015;47:17-23. PMID 26010959
49: Koh S, Wirrell E, Vezzani A, et al. Proposal to optimize evaluation and treatment of febrile infection-related epilepsy syndrome (FIRES): a report from FIRES workshop. Epilepsia Open 2021;6(1):62-72. PMID 33681649
50: Korthagen NM, van Moorsel CHM, Kazemier KM, Ruven HJT, Grutters JC. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics 2012;64(5):371-7. PMID 22322675
51: Kothur K, Bandodkar S, Wienholt L, et al. Etiology is the key determinant of neuroinflammation in epilepsy: elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus. Epilepsia 2019;60(8):1678-88. PMID 31283843
52: Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia 2011;52(11):1956-65. PMID 21883180
53: Kramer U, Shorer Z, Ben-Zeev B, et al. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol 2005;20(3):184-7. PMID 15832606
54: Lai YC, Abou-El-Kheir G, Nguyen T, Haneroff M, Riviello JJ, Muscal E. Systemic inflammatory markers and EEG features of children with FIRES receiving anakinra. Ann Clin Transl Neurol 2023;10(3):440-6. PMID 36645080
55: Lai YC, Muscal E, Wells E, et al. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol 2020;7(12):2467-74. PMID 33506622
56: Lattanzi S, Leitinger M, Rocchi C, et al. Unraveling the enigma of new-onset refractory status epilepticus: a systematic review of aetiologies. Eur J Neurol 2022;29(2):626-47. PMID 34661330
57: Legriel S. Hypothermia as a treatment in status epilepticus: a narrative review. Epilepsy Behav 2019;101(Pt B):106298. PMID 31133509
58: Lin JJ, Lin KL, Hsia SH, Wang HS; Cheese Study Group. Therapeutic hypothermia for febrile infection-related epilepsy syndrome in two patients. Pediatr Neurol 2012;47(6):448-50. PMID 23127267
59: Lin WS. The nuances of immunotherapy for NORSE/FIRES. Epilepsia 2022;63(12):3212-4. PMID 36266948
60: Matthews E, Alkhachroum A, Massad N, et al. New-onset super-refractory status epilepticus: a case series of 26 patients. Neurology 2020;95(16):e2280-5. PMID 32943479
61: Meletti S, Giovannini G, d’Orsi G, et al. New-onset refractory status epilepticus with claustrum damage: definition of the clinical and neuroimaging features. Front Neurol 2017;8:111. PMID 28396650
62: Meletti S, Slonkova J, Mareckova I, et al. Claustrum damage and refractory status epilepticus following febrile illness. Neurology 2015;85(14):1224-32. PMID 26341869
63: Mikaeloff Y, Jambaqué I, Hertz-Pannier L, et al. Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis. Epilepsy Res 2006;69(1):67-79. PMID 16469483
64: Nabbout R, Matricardi S, De Liso P, et al. Ketogenic diet for super-refractory status epilepticus (SRSE) with NORSE and FIRES: Single tertiary center experience and literature data. Front Neurol 2023;14:1134827. PMID 37122314
65: Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010;51(10):2033-7. PMID 20813015
66: Nabbout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol 2011;10(1):99-108. PMID 21163447
67: Patil SB, Roy AG, Vinayan KP. Clinical profile and treatment outcome of febrile infection-related epilepsy syndrome in South Indian children. Ann Indian Acad Neurol 2016;19(2):188-94. PMID 27293328
68: Peng P, Peng J, Yin F, et al. Ketogenic diet as a treatment for super-refractory status epilepticus in febrile infection-related epilepsy syndrome. Front Neurol 2019;10:423. PMID 31105638
69: Perulli M, Cicala G, Turrini I, et al. Fighting autoinflammation in FIRES: the role of interleukins and early immunomodulation. Epilepsy Behav Rep 2022;18:100531. PMID 35356746
70: Remy KE, Custer JW, Cappell J, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis: a review with pooled analysis and critical care emphasis. Front Pediatr 2017;5:250. PMID 29226117
71: Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis 2015;10:19. PMID 25758134
72: Sa M, Singh R, Pujar S, et al. Centromedian thalamic nuclei deep brain stimulation and anakinra treatment for FIRES - two different outcomes. Eur J Pediatr Neurol 2019;23(5):749-54. PMID 31446001
73: Sahin M, Menache CC, Holmes GL, Riviello JJ. Outcome of severe refractory status epilepticus in children. Epilepsia 2001;42(11):1461-7. PMID 11879350
74: Saitoh M, Kobayashi K, Ohmori I, et al. Cytokine-related and sodium channel polymorphism as candidate predisposing factors for childhood encephalopathy FIRES/AERRPS. J Neurol Sci 2016;368:272-6. PMID 27538648
75: Sakuma H, Awaya Y, Shiomi M, et al. Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. Acta Neurol Scand 2010;121(4):251-6. PMID 20028339
76: Sakuma H, Tanuma N, Kuki I, Takahashi Y, Shiomi M, Hayashi M. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatry 2015;86(7):820-2. PMID 25398790
77: Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;79(11):1094-100. PMID 22933737
78: Schoeler NE, Simpson Z, Zhou R, Pujar S, Eltze C, Cross JH. Dietary management of children with super-refractory status epilepticus: a systematic review and experience in a single UK tertiary centre. Front Neurol 2021;12:643105. PMID 33776895
79: Sculier C, Aguilar CB, Gaspard N, et al. Clinical presentation of new onset refractory status epilepticus in children (the pSERG Cohort). Epilepsia 2021;62(7):1629-42. PMID 34091885
80: Sculier C, Gaspard N. New onset refractory status epilepticus (NORSE). Seizure 2019;68(May):72-8. PMID 30482654
81: Sculier C, Gaspard N. New-onset refractory status epilepticus and febrile infection-related epilepsy syndrome. Curr Opin Neurol 2023;36(2):110. PMID 36762646
82: Starvropoulos I, Khaw JH, Valentin A. Neuromodulation in new-onset refractory status epilepticus. Front Neurol 2023;14:1195844. PMID 37388544
83: Stredny CM, Case S, Sansevere AJ, Son M, Henderson L, Gorman MP. Interleukin-6 blockade with tocilizumab in anakinra-refractory febrile infection-related epilepsy syndrome (FIRES). Child Neurology Open 2020;7:2329048X20979253. PMID 33403221
84: Tan TH, Perucca P, O’Brien TJ, Kwan P, Monif M. Inflammation, ictogenesis, and epileptogenesis: an exploration through human disease. Epilepsia 2021;62(2):303-24. PMID 33316111
85: Taraschenko O, Pavuluri S, Schmidt CM, Pulluru YR, Gupta N. Seizure burden and neuropsychological outcomes of new-onset refractory status epilepticus: systematic review. Front Neurol 2023;14:1095061. PMID 36761344
86: Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology 2014;82(8):665-70. PMID 24453083
87: van Baalen A, Häusler M, Boor R, et al. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia 2020;51(7):1323-8. PMID 20345937
88: van Baalen A, Häusler M, Plecko-Startinig B, et al. Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES. Neuropediatrics 2012;43(4):209-16. PMID 22911482
89: van Baalen A, Vezzani A, Häusler M, Kluger G. Febrile infection-related epilepsy syndrome: clinical review and hypotheses of epileptogenesis. Neuropediatrics 2017;48(1):5-18. PMID 27919115
90: Van Lierde I, Van Paesschen W, Dupont P, Maes A, Sciot R. De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: a review of six cases. Acta Neurol Belg 2003;103(2):88-94. PMID 12892002
91: Varughese RT, Karkare S, Poduri A, Kothare SV. Child neurology: initial presentation of PCDH19-related epilepsy with new-onset refractory status epilepticus and treatment with anakinra. Neurology 2022;99(5):208-11. PMID 35914944
92: Wadayama T, Shimizu M, Yata T, et al. Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment. J Neuroimmunol 2022;363:577789. PMID 34973472
93: Westbrook C, Subramaniam T, Seagren RM, et al. Febrile infection-related epilepsy syndrome treated successfully with anakinra in a 21-year-old woman. WMJ 2019;118(3):135-9. PMID 31682750
94: Wickstrom R, Taraschenko O, Dilena R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) incl. febrile infection-related epilepsy syndrome (FIRES): statements and supporting evidence. Epilepsia 2022;63(11):2840-64. PMID 35997591
95: Wilder-Smith EPV, Lim ECH, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singap 2005;34(7):417-20. PMID 16123813
96: Wu J, Lan X, Yan L, et al. A retrospective study of 92 children with new-onset refractory status epilepticus. Epilepsy Behav 2021;125:108413. PMID 34794014
97: Yanagida A, Kanazawa N, Kaneko J, et al. Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus. Neurol Neuroimmunol Neuroinflamm 2020;7(5):e849. PMID 32727813
98: Yang JH, Nataraj S, Sattar S. Successful treatment of pediatric FIRES with anakinra. Pediatr Neurol 2021;114:60-1. PMID 33227629
99: References especially recommended by the author or editor for general reading.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Nicolas Gaspard PhD

Dr. Gaspard of Université Libre de Bruxelles and Yale University School of Medicine has no relevant financial relationships to disclose.
See Profile
Claudine Sculier MD

Dr. Sculier of Erasme Hospital has no relevant financial relationships to disclose.
See Profile

Editor

Solomon L Moshé MD

Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile

Patient Profile

Sex preponderance: Unclear

Female preponderance in adults

Male preponderance in children
Heredity: No hereditary factors
Population groups selectively affected: School-aged children

Young adults

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

Associated Disorders

Primary autoimmune encephalitis
Paraneoplastic encephalitis
Genetic encephalopathy
Postinfectious disorders
Infectious encephalitis

Differential Diagnosis

No occupation group selectively affected

Also Relevant

Antibody-mediated epilepsies
Generalized tonic-clonic status epilepticus
Genetic epilepsy with febrile seizures plus

Clinical Categories

Epilepsy & Seizures

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Media

References

Contributors

Authors

Editor

Patient Profile

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Media

References

Contributors

Authors

Editor

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

This is an article preview.
Start a Free Account
to access the full version.